Viridian Therapeutics, Inc.\DE (VRDN) Current Assets (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Current Assets history runs 14 years deep, the most recent figure standing at $784.7 million for Q1 2026.

• In Q1 2026, Current Assets rose 19.4% year-over-year to $784.7 million; the TTM figure through Mar 2026 stood at $784.7 million (up 19.4% YoY), while the FY2025 annual figure was $894.2 million, up 21.09% from the prior year.
• Current Assets for Q1 2026 stood at $784.7 million, down from $894.2 million in the prior quarter.
• The five-year high for Current Assets was $894.2 million in Q4 2025, with the low at $166.2 million in Q2 2022.
• The 5-year median for Current Assets is $571.9 million (2025), against an average of $526.7 million.
• The sharpest annual moves came in 2023 and 2024: Current Assets retreated 25.96% in 2023, then soared 136.96% in 2024.
• Viridian Therapeutics, Inc.\DE's Current Assets stood at $431.2 million in 2022, then gained by 12.83% to $486.5 million in 2023, then surged by 51.8% to $738.5 million in 2024, then rose by 21.09% to $894.2 million in 2025, then decreased by 12.24% to $784.7 million in 2026.
• Business Quant data shows VRDN's Current Assets at $784.7 million in Q1 2026, $894.2 million in Q4 2025, and $571.9 million in Q3 2025.